Opthea (ASX:OPT) raises $50 million in Institutional Placement

[videojs_hls url=’//du7x25at22z7c.cloudfront.net/274659/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/Headlines02_360_191202.jpg’]

Biopharmaceutical company Opthea (ASX:OPT) today announced that the company has received commitments from sophisticated and institutional investors in Australia and the United Kingdom to raise $50 million via a private placement.

The proceeds from the Placement will be used to fund further activities to support the late-stage clinical development of OPT-302 as a therapy for wet Age-related Macular Degeneration (wet AMD).

The financing follows the recent reporting of outcomes from Opthea’s Phase 2b clinical study in which OPT-302 combination therapy demonstrated statistically significant and superior gains in visual acuity compared to ranibizumab (Lucentis®) monotherapy at 24 weeks in a trial of 366 treatment-naïve wet AMD patients.

The Placement was conducted at a fixed price of $2.65 per New Share.

Shares in Opthea (ASX:OPT) closed 6.19 per cent lower at $2.73 on Friday.
 
Copyright 2019 – Finance News Network

Source: Finance News Network